MB
At a glance
The past 12 months
Clients
0
past 12 months
Filings
0
last filed Jul 2024
Specific issues
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Clients
No client work disclosed in the past 12 months.
Past clients1
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗